Compare First Trust NASDAQ 100 Technology Index Fund (QTEC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ 100 Technology Index Fund vs Recursion Pharmaceuticals Inc — how do they compare? First Trust NASDAQ 100 Technology Index Fund trades at $306.13, while Recursion Pharmaceuticals Inc trades at $3.01 (market cap $1.63B). The key difference: First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| QTEC | RXRX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $335.74 | $6.79 |
52-Week Low | $207.03 | $2.84 |
Market Cap | — | $1.63B |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QTEC, the First Trust NASDAQ-100-Technology Sector ETF, trades at $301.50, up 0.53% on the day. The technical outlook is bearish, with moving averages signaling a downtrend and key support at $285. Recent news highlights its role as a smart beta ETF providing broad technology sector exposure since its 2006 launch, though some reports question if recent large sales signal caution around overheated AI and chip stocks.
The ETF's outlook is clouded by bearish technicals and sector concentration risks, but its equal-weighted access to top tech firms offers targeted exposure. Key risks include market volatility and sector-specific headwinds, while the neutral oscillator readings suggest potential for stabilization near current levels.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
